悦康药业：子公司在国际知名期刊发表AI快速高效设计和筛选药物的学术论文

Core Viewpoint - The publication of the AI drug development paper and the authorization of four AI algorithm patents signify the enhancement of the company's drug development capabilities [3]. Group 1: AI Drug Development - The company’s subsidiary published a paper on a deep learning model named AVP-GPT, designed for antiviral peptide discovery, in the journal "Viruses" [1]. - AVP-GPT utilizes a Transformer language model and multimodal architecture, successfully identifying potential high-activity peptide drug molecules, thus revolutionizing the peptide drug discovery and design process [2]. - The model significantly accelerates the development of new antiviral peptide drugs, integrating AI into various drug development platforms [2]. Group 2: Integration of AI in Drug Development - The company has integrated AI into its peptide innovation drug development platform, nucleic acid drug development platform, tumor mRNA vaccine platform, LNP delivery technology platform, and cell and gene therapy platform [3]. - This integration has greatly improved the speed and quality of new drug development [3]. - The company aims to leverage AI across the entire drug development process, including target discovery, drug design, screening, chemical synthesis, process development, and parameter optimization [3].